ArticleCureus2025
A 15-Year-Old Boy in Long-Term Remission of Epileptic Seizures With Infantile-Onset Attenuated Nonketotic Hyperglycinemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonketotic hyperglycinemia (NKH) is a rare autosomal recessive disorder caused by defects in the glycine cleavage system. Most patients with early-onset NKH present with severe manifestations, including poor neurological outcomes and refractory seizures. However, a proportion of neonatally presenting patients exhibit the attenuated phenotype, characterized by variable clinical features. We report a boy with infantile-onset NKH who achieved long-term seizure remission into adolescence. A three-month-old boy developed infantile spasms refractory to standard antiepileptic drugs and worsened by valproic acid. Laboratory findings revealed elevated glycine levels in plasma and cerebrospinal fluid with an increased CSF/plasma ratio of glycine. A glycine breath test indicated partial reduction of glycine metabolism. He was diagnosed with early-onset NKH at nine months, and thereafter, specific treatments were started with sodium benzoate and dextromethorphan. He exhibited severe developmental delay under sustained seizure control. Genetic testing at 11 years of age revealed compound heterozygous variants in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.